Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC01 in Chronic HIV Infection Undergoing Analytical Treatment Interruption
NCT02471326Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2015
- Primary completion
- Apr 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VRC01 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Grade 3 or Higher Adverse Events at 48 weeks. Started Jul 2015; status: completed.
02
Drugs
VRC01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02471326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471326.